European Medicines Agency (EMA) Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Talk Evidence covid-19 update - How will we know if a vaccine works?
Vaccines have been in the news this week - but when you dig into the stories, it turns out that the hype is about phase 1 trials. We're a long way from being sure any of the 150 possible vaccines being developed actually work. In this talk evidence we're talking to a researcher, a regulator, and a manufacturer about the way in covid-19 is upending normal vaccine development, which hurdles they'll have to reach to get onto the market, and how we'll know which one to choose when they are there. This week (1.10) We said that covid would have a knock-on effect on other treatments, and Helen looks at some research into acut...
Source: The BMJ Podcast - July 17, 2020 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Talk Evidence - eating less, drinking less, drug approval data
Talk Evidence is back, with your monthly take on the world of EBM with Duncan Jarvies and GPs Carl Heneghan (also director for the Centre of Evidence Based Medicine at the University of Oxford) and Helen Macdonald (also The BMJ's UK research Editor). This month Carl talks about evidence that restricting your diet might improve health at a population level (1.50) Helen talks about the data on a drop in alcohol consumption amongst Scots (7.04) A listener questions the team about their take on Tramadol (13.45) Helen talks about the problems wi th the trials we use to regulate drugs (18.00) And Carl explains why drug sho...
Source: The BMJ Podcast - October 4, 2019 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Talk Evidence - eating less, drinking less, drug approval data
Talk Evidence is back, with your monthly take on the world of EBM with Duncan Jarvies and GPs Carl Heneghan (also director for the Centre of Evidence Based Medicine at the University of Oxford) and Helen Macdonald (also The BMJ's UK research Editor). This month Carl talks about evidence that restricting your diet might improve health at a population level (1.50) Helen talks about the data on a drop in alcohol consumption amongst Scots (7.04) A listener questions the team about their take on Tramadol (13.45) Helen talks about the problems with the trials we use to regulate drugs (18.00) And Carl explains why drug short...
Source: The BMJ Podcast - October 4, 2019 Category: General Medicine Authors: BMJ Group Source Type: podcasts

EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer
The European Medicines Agency have announced their recommendation to restrict the use of pembrolizumab and atezolizumab to the first-line treatment of urothelial cancer patients with high PD-L1 expres... Author: VJOncology Added: 08/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 22, 2018 Category: Cancer & Oncology Source Type: podcasts

Vinay Prasad - Cancer drugs from an oncologist point of view
Last week we published some new research which showed that 2/3 of new cancer drugs approved by the European Medicines Agency - the drug regulator for Europe - didn ’t have any evidence of improved life expectancy or quality of life. In this interview, Vinau Prasad, ematologist-oncologist and Assistant Professor of Medicine at the Oregon Health and... (Source: The BMJ Podcast)
Source: The BMJ Podcast - October 13, 2017 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Vinay Prasad - Cancer drugs from an oncologist point of view
Last week we published some new research which showed that 2/3 of new cancer drugs approved by the European Medicines Agency - the drug regulator for Europe - didn’t have any evidence of improved life expectancy or quality of life. In this interview, Vinau Prasad, ematologist-oncologist and Assistant Professor of Medicine at the Oregon Health and Sciences University, explains how we came to accept surrogate measures in oncology trials, and how he tries to navigate the evidence for his patients. Read his editorial: http://www.bmj.com/content/359/bmj.j4528 (Source: The BMJ Podcast)
Source: The BMJ Podcast - October 13, 2017 Category: General Medicine Authors: BMJ Group Source Type: podcasts

A maladaptive pathway to drug approval
The European Medicines Agency (EMA) has embraced a new model of drug testing and marketing called “adaptive pathways”, allowing new drugs for “unmet medical needs” to be launched on the market faster, on the basis of fewer data. While industry claims this is necessary, an analysis on thebmj.com looks at the assumptions underlying the new pathway, and raises concerns about the negative i mpact on patient safety and the cost of healthcare. To discuss, we're joined by Courtney Davis, senior lecturer at King’s College London, Peter Gøtzsche, director of the Nordic Cochrane Centre and Joel Lexchin, a professor at Y...
Source: The BMJ Podcast - August 19, 2016 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

A maladaptive pathway to drug approval
The European Medicines Agency (EMA) has embraced a new model of drug testing and marketing called “adaptive pathways”, allowing new drugs for “unmet medical needs” to be launched on the market faster, on the basis of fewer data. While industry claims this is necessary, an analysis on thebmj.com looks at the assumptions underlying the new pathway, and raises concerns about the negative impact on patient safety and the cost of healthcare. To discuss, we're joined by Courtney Davis, senior lecturer at King’s College London, Peter Gøtzsche, director of the Nordic Cochrane Centre and Joel Lexchin, a professor at Yo...
Source: The BMJ Podcast - August 19, 2016 Category: General Medicine Authors: BMJ Group Source Type: podcasts

Should we still be using hydroxyethyl starch?
Large trials show that hydroxyethyl starch increases the risk of death, kidney injury, and bleeding. So why does the European Medicines Agency still allow its use? Helen Macdonald, analysis editor for The BMJ, discusses the issue with Christiane Hartog, a lecturer in intensive care medicine at Jena University Hospital in Germany, and one of the... (Source: The BMJ Podcast)
Source: The BMJ Podcast - November 11, 2014 Category: Journals (General) Authors: BMJ talk medicine Source Type: podcasts

Should we still be using hydroxyethyl starch?
Large trials show that hydroxyethyl starch increases the risk of death, kidney injury, and bleeding. So why does the European Medicines Agency still allow its use? Helen Macdonald, analysis editor for The BMJ, discusses the issue with Christiane Hartog, a lecturer in intensive care medicine at Jena University Hospital in Germany, and one of the authors of an analysis paper on thebmj.com Read the full analysis paper: www.bmj.com/content/349/bmj.g5981 (Source: The BMJ Podcast)
Source: The BMJ Podcast - November 11, 2014 Category: General Medicine Authors: BMJ Group Source Type: podcasts